FutuRx
Michael Martin is the Global Head of Takeda Ventures, Inc. (TVI) and is based in San Diego, California. His professional background includes venture capital, pharma business development, and broad R&D experiences with an integral role in the discovery and development of 17 innovative investigational drugs and 4 commercial products. Prior to joining TVI, Michael was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for sourcing and transacting technologies and early-stage pipeline programs. He has held executive and scientific roles with Intellikine (acquired by Takeda), TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals, and Monsanto Corporation. Michael earned his doctorate in Medicinal Chemistry from the University of Illinois and holds an M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
FutuRx
FutuRx is a biotech incubator founded by three leading global healthcare players. FutuRx leverages its access to the Israeli biotech industry, and to leading research institutes in Israel and worldwide, to identify and develop highly innovative technologies. Experts at Takeda, J&J, and OrbiMed are deeply involved in the project selection process and during the incubator period of each company. The result is a clear impact on the efficient translation of innovative research to clinically meaningful products.